

1 **Cardiovascular drugs approved for heart failure with reduced ejection fraction and/or**  
2 **post-myocardial infarction exert consistent effects in both populations: A meta-analysis**  
3 **and meta-regression of randomized controlled trials**

4  
5 Christopher Dasaro, BS;<sup>1</sup> Alyson Haslam, PhD;<sup>2</sup> Vinay Prasad, MD, MPH<sup>2</sup>

6 <sup>1</sup>Lewis Katz School of Medicine at Temple University, 3500 N Broad St, Philadelphia, PA  
7 19140

8 <sup>2</sup>Department of Epidemiology and Biostatistics, University of California San Francisco, 550 16th  
9 St, 2nd Fl, San Francisco, CA 94158

10 <sup>1,2</sup> *This author takes responsibility for all aspects of the reliability and freedom from bias of the*  
11 *data presented and their discussed interpretation*

12  
13 Corresponding author:

14 Christopher Dasaro, BS

15  
16 Lewis Katz School of Medicine at Temple University, 3500 N Broad St, Philadelphia, PA 19140

17 Email: tum91199@temple.edu

18  
19 **Sources of Funding & Disclosures:** Vinay Prasad's Disclosures. (Research funding) Arnold

20 Ventures (Royalties) Johns Hopkins Press, Medscape, and MedPage (Honoraria) Grand

21 Rounds/lectures from universities, medical centers, non-profits, and professional societies.

22 (Consulting) UnitedHealthcare and OptumRX. (Other) Plenary Session podcast has Patreon

23 backers, YouTube, and Substack. Alyson Haslam has no disclosures to report. Christopher

24 Dasaro has no disclosures to report.

25

26 **Key Terms:** Heart failure with reduced ejection fraction; cardiovascular drug approvals; meta-  
27 regression; evidence appraisal  
28

29 **Abstract:**

30 **Background:** Heart failure (HF) following an acute myocardial infarction (post-MI HF) has  
31 been studied as an additional sub-type of HF to broaden the indications for HF drugs. Post-MI  
32 HF and HFrEF are pathophysiologically similar and share pharmacotherapies. In this meta-  
33 analysis, we examined the concordance between all-cause mortality data for drugs indicated for  
34 HFrEF and post-MI HF. We used our analysis to calculate the projected all-cause mortality  
35 hazard ratios (HRs) for the pending dapagliflozin (DAPA-MI) and empagliflozin (EMPACT-MI)  
36 post-MI HF trials.

37 **Methods:** Using CenterWatch and UpToDate, we identified all FDA-approved drugs for NYHA  
38 Class II to IV HFrEF. We searched each of these drugs on FDALabel and ClinicalTrials.gov to  
39 identify their registration trials measuring all-cause mortality for HFrEF and, if available, in the  
40 post-MI setting—including trials where participants displayed a left ventricular ejection fraction  
41 of <40% (“post-MI HF”). For each of the included studies, we extracted the all-cause mortality  
42 HRs, their 95% confidence intervals, and the control-group used. For all drugs studied in both  
43 indications, we plotted the all-cause mortality HRs for HFrEF against those for post-MI (HF) and  
44 calculated the linear regressions.

45 **Results:** This meta-regression pooled data from 29 completed trials underlying 20 drugs.  
46 Two pending trials were also analyzed. Nine drugs (metoprolol, carvedilol, spironolactone,  
47 eplerenone, sacubitril-valsartan, lisinopril, enalapril, valsartan, losartan) had all-cause  
48 mortality data in both HFrEF and post-MI generally, with a linear coefficient of  
49 determination of 0.93. Five of these drugs (carvedilol, eplerenone, sacubitril-valsartan,  
50 valsartan, losartan) were studied in both HFrEF and non-acute post-MI HF, displaying a

51 linear coefficient of determination of 0.99. Using our model, we predict the all-cause  
52 mortality HRs that will be observed in the EMPACT-MI and DAPA-MI trials will be 0.85  
53 and 0.89, respectively.

54 **Conclusions:** In this meta-regression of registration trials for drugs studied in both HFrEF  
55 and post-MI (HF), all-cause mortality effects were highly concordant. We also find  
56 asymmetries in the assessment of HF drug indications, whereby drugs are seldom assessed  
57 for an all-cause mortality benefit in both HFrEF and in post-MI HF. Future studies may  
58 use these results to guide future HF RCT development.

59 **Key Terms:** Heart failure with reduced ejection fraction; cardiovascular drug approvals;  
60 meta-regression; evidence appraisal

61 **Introduction:**

62 Heart Failure (HF) is a common clinical syndrome characterized by impaired cardiac  
63 output. HF can be characterized as having a preserved (HFpEF) or reduced (HFrEF) ejection  
64 fraction – with  $\leq 40\%$  defining the latter. In addition to HFpEF and HFrEF, heart failure  
65 following acute myocardial infarction (post-MI HF) has been studied as an additional sub-type of  
66 HF to broaden the indications for a given pharmacotherapy. This sequela is characterized by left  
67 ventricular dysfunction following an acute MI.

68 Myocardial infarctions are treated with several drugs—namely antiplatelet agents, beta  
69 blockers, statins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers  
70 (ARBs), and mineralocorticoid receptor antagonists (MRAs) – with varied introduction of such  
71 therapies depending on the time since infarct<sup>1</sup>. Both HFrEF and post-MI HF are similar in  
72 pathophysiology and share medical therapies, yet both occupy unique niches for which  
73 treatments can claim market-share and broaden their indications.

74 We sought to examine the concordance of data supporting the use of select  
75 pharmacological therapies in HFrEF and post-MI HF. To do so, we aimed to characterize all of  
76 the regulatory trials underpinning the use of HFrEF agents in post-MI HF in terms of their all-  
77 cause mortality benefits (or lack thereof). In addition to clarifying the scope in which these drugs  
78 are indicated, our analysis provides grounds for preliminarily predicting outcomes in pending HF  
79 trials. In our case, we used this analysis to impute the projected all-cause mortality hazard ratios  
80 (HRs) for the pending dapagliflozin (DAPA-MI)<sup>2</sup> and empagliflozin (EMPACT-MI)<sup>3</sup> post-MI  
81 HF trials. We later broadened this model to predict the all-cause mortality HRs for drugs with  
82 missing trials for either HFrEF or post-MI HF.

83

84 **Methods:**

85           We systematically identified and characterized the trials supporting the approval of drugs  
86 indicated for HFrEF. First, we downloaded the UpToDate page detailing primary and secondary  
87 pharmacologic therapies for New York Heart Association (NYHA) functional classification II to  
88 IV HFrEF<sup>4</sup>. We also consulted CenterWatch<sup>5</sup> for additional drugs labeled US Food and Drug  
89 Administration (FDA)-Approved for Heart Failure. All drugs included were confirmed to be  
90 approved by the US FDA.

91           From this list of US FDA-regulatory approvals for HF, we identified the registration  
92 clinical trials supporting their use for HFrEF and, if indicated, in the post-MI setting. For each  
93 drug, we searched on the FDALabel database<sup>6</sup> and its associated Structured Product Labeling  
94 (SPL) document to determine the drug's specific indication(s) and clinical trial(s) underpinning  
95 its approval. In instances where the SPL document failed to provide trial information (e.g trial  
96 name, NCT number), we searched for the drug's registration trial on ClinicalTrials.gov using the  
97 particular drug as the "intervention", and limited our search to randomized phase II, III, and IV  
98 trials in the English language. When reviewing the resulting trials, articles were included in our  
99 analysis only if all-cause mortality was a reported endpoint. We excluded articles that were  
100 pooled or secondary analyses; were retracted or inaccessible; contained fewer than 1,000  
101 participants; were done in specific disease sub-populations (e.g only those with diabetes mellitus  
102 type 2); did not measure all-cause mortality, or only measured surrogate measures of morbidity  
103 (e.g., brain natriuretic peptide [BNP] levels).

104           We also characterized all of the post-MI studies by maximum LVEF permitted and the  
105 time between MI-onset and randomization. Noting the time-since-MI allowed us to assess how  
106 soon after the MI that a drug was initiated. Characterizing trials in this way may be relevant

107 because the timing of LV dysfunction post-MI can logarithmically impact the risk of mortality<sup>7</sup>  
108 and thus could obscure a direct comparison of the post-MI all-cause mortality benefits between  
109 drugs. A time-to-randomization of <3 days was considered the “acute” post-MI phase, and  $\geq 3$   
110 days was considered the “non-acute” post-MI phase<sup>7</sup>.

111 For each of the included studies, we extracted the reported all-cause mortality HRs and  
112 their associated 95% confidence intervals. Additionally, we noted whether the trial used an  
113 active- or placebo-control; whether a trial existed for HFrEF, post-MI, or both; the number of  
114 participants randomized; and the LVEF and time-to-randomization used as inclusion criteria in  
115 any post-MI trials. For all drugs with both HFrEF and post-MI trials, we plotted the all-cause  
116 mortality HRs against each other in an x-y plane and calculated a linear regression. The  
117 confidence intervals, if available, for each condition are represented by the width and height of  
118 the ellipse surrounding that drug. All analyses were conducted using *Python*<sup>8</sup>.

119 We calculated regression coefficients and plotted the linear correlation for all drugs  
120 studied in HFrEF and post-MI— including both in the acute (time-to-randomization of <3 days)  
121 and non-acute ( $\geq 3$  days) post-MI phase. We later isolated the drugs studied in HFrEF and the  
122 non-acute post-MI phase specifically, which incidentally isolated the post-MI trials where  
123 participants displayed a LVEF of  $\leq 40\%$  (“non-acute post-MI HF”). We also calculated and  
124 plotted separate correlations for drugs studied in either placebo- or actively-controlled trials.

125 From the resulting regression equations, we were able to (1) calculate the projected all-  
126 cause mortality HRs for the pending DAPA-MI and EMPACT-MI trials; and (2) estimate the all-  
127 cause mortality HRs for drugs with data in only one of the two indications. Specifically, we used  
128 this same model to impute the missing all-cause mortality metrics across multiple classes of  
129 drugs with missing data reported: ACE Inhibitors, ARBs, beta blockers, and MRAs/other class.

130 In accordance with 45 CFR §46.102(f), this study was not submitted for University of  
131 California, San Francisco institutional review board approval because it involved publicly  
132 available data and did not involve individual patient data.

### 133 **Results**

134 Our search yielded 22 drugs from UpToDate and 11 from CenterWatch (**Table 1**). Eight  
135 drugs (sacubitril-valsartan, metoprolol, valsartan, dapagliflozin, empagliflozin,  
136 isosorbide/hydralazine, vericiguat, and ivabradine) were featured in both sources. In total, we  
137 found 23 unique drugs and 31 unique trials. Three drugs (ferric carboxymaltose, sotagliflozin,  
138 and canagliflozin) had registration trials done in specific disease sub-populations (e.g,  
139 exclusively those with iron-deficiency anemia or diabetes mellitus type 2), and were thus  
140 excluded from our analysis. Eight drugs had all-cause mortality data available for HFrEF only;  
141 three drugs had all-cause mortality data for post-MI only; and nine drugs (metoprolol, carvedilol,  
142 spironolactone, eplerenone, sacubitril-valsartan, lisinopril, enalapril, valsartan, losartan) had all-  
143 cause mortality data for both conditions (**Table 2**).

144 In addition to whether each drug was studied in both HFrEF and post-MI, we  
145 characterized the trials as having active-controls, placebo-controls, or a mix of the two. Of the  
146 nine drugs with all-cause mortality data in both conditions, five drugs (metoprolol, carvedilol,  
147 eplerenone, enalapril, and spironolactone) were studied against placebo in both indications. In  
148 contrast, two drugs (sacubitril-valsartan and losartan) were compared against active controls in  
149 both HFrEF and post-MI. Of note, only sacubitril-valsartan used two distinct active controls  
150 (enalapril in HFrEF; ramipril in post-MI); losartan was studied against captopril in both  
151 indications.



152 Two of the eight drugs (lisinopril and valsartan) had “mixed” active/placebo controls,  
153 whereby only one trial was placebo-controlled while the other had an active control. Specifically,  
154 lisinopril’s registration trial for HFrEF compared high (32.5-35 mg/day)- vs low (2.5mg-5mg)-  
155 dose lisinopril<sup>9</sup>, while its post-MI counterpart was placebo-controlled<sup>10</sup>. Valsartan, in contrast,  
156 was compared against placebo in HFrEF<sup>11</sup> and against captopril in post-MI HF<sup>12</sup>.

157 **Figure 1** shows the drugs’ all-cause mortality data reported in the post-MI survival trials  
158 as a function of those reported in HFrEF. The drugs are differentiated by control arm and have a  
159 gray ellipse representing the 95% confidence interval along either axis. Of note, the confidence  
160 intervals for metoprolol and enalapril were not provided in their registration trials for post-MI  
161 (MIAMI<sup>13</sup> and CONSENSUS-II<sup>14</sup>, respectively) and thus do not have an ellipse. From this  
162 unadjusted regression model, we calculated an  $R^2$  of 0.87 and a correlation of 0.93.

163 We further analyzed the post-MI trials to further characterize them by time-since-  
164 MI/time-to-randomization. We differentiated drugs that were studied in the acute post-MI phase  
165 (<3 days) from those studied in the non-acute ( $\geq 3$  days) post-MI phase. **Figure 2** illustrates the  
166 time-since-MI inclusion criteria, in days, for all of the post-MI trials included in our analysis that  
167 reported such data. Four trials (GISSI-3, ALBATROSS<sup>15</sup>, CONSENSUS-II, and MIAMI)  
168 studied their respective drug (lisinopril, spironolactone, enalapril, and metoprolol) only in the  
169 acute post-MI phase. Past reports indicate that the development of HF more than 3 days post-MI  
170 is associated with a 43% increase in mortality than when developed in the first 3 days<sup>7</sup>. Thus, we  
171 re-analyzed the data in Figure 1 after removing these trials, resulting in an improvement in the  
172 coefficient of determination ( $R^2$  of 0.98, **Figure 3**). Excluding these trials also allowed us to  
173 isolate all of the post-MI trials that only allowed LVEFs  $\leq 40\%$  (“post-MI HF”) (**Table S1**).

174 **Figure 4A** and **4B** splits drugs tested against placebo (in at least one of its trials) and  
175 those tested against an active-control (in at least one of its trials). We found coefficients of  
176 determination of 0.98 among the active-controlled trials and 1.00 in the placebo-controlled trials.  
177 As EMPACT-MI and DAPA-MI are projected to be placebo-control trials, we imputed their all-  
178 cause mortality benefits from the linear regression calculated in Figure 4A. This model  
179 predicted all-cause mortality HRs of 0.89 and 0.85, for trials of DAPA-MI and EMPACT-MI,  
180 respectively (Figure 4A).

181 Using the placebo-controlled linear regression modeled in Figure 4A, we repeated our  
182 all-cause mortality predictions for all drugs that had missing all-cause mortality data in either  
183 HFrEF or post-MI HF. We broke up this analysis by drug class and reported the HRs as cartesian  
184 coordinates (**Figure S1, panels A-D**). Figure S1 shows the missing all-cause mortality metrics  
185 across multiple classes of drugs with missing data reported: ACE Inhibitors (panel A), ARBs  
186 (panel B), MRAs/other class (panel C), and beta blockers (panel D).

187

## 188 **Discussion:**

189 We found among 23 unique drugs indicated for HF, only nine (39%) currently have trials  
190 measuring all-cause mortality in both NYHA II-IV HFrEF and post-MI. When accounting for  
191 drugs that were studied only in the acute phase following an MI and limited patients to a LVEF  
192 of <40%, only five (22%) drugs measured all-cause mortality in both HFrEF and non-acute post-  
193 MI HF. Of these five drugs, two were studied in placebo-controlled trials while three partially or  
194 entirely used active-controls. Conversely, eight drugs (35%) had survival data for only HFrEF,  
195 while three (13%) others had data only for post-MI HF. These data points to pervasive

196 asymmetries in the treatment of HF, whereby drugs are seldom assessed for an all-cause  
197 mortality benefit in both HFrEF and in post-MI HF.

198       Using the model in Figure 4A, we calculated the expected all-cause mortality HRs for the  
199 pending dapagliflozin and empagliflozin post-MI trials. Per the published protocols, the  
200 EMPACT-MI and DAPA-MI are placebo-controlled trials. We estimate the HR in these ongoing  
201 trials to be 0.85 and 0.89, respectively.

202       Similarly, we used this strategy to extrapolate the all-cause mortality HRs for 12 (52%)  
203 drugs missing either HFrEF or post-MI HF data (Figure S1A-D). We grouped this analysis by  
204 drug class: ACE inhibitors, ARBs, beta blockers, and MRAs/other classes. The ACE inhibitor  
205 class had the most “missing” data, with this analysis filling in all-cause mortality gaps for four  
206 drugs. This is because the efficacies of three ACE inhibitors—captopril, trandolapril, and  
207 ramipril—were studied in three placebo-controlled post-MI HF trials (SAVE (1992)<sup>16</sup>, TRACE  
208 (1995)<sup>17</sup>, and AIRE (1993)<sup>18</sup>, respectively), but not in HFrEF. The extrapolation of all-cause  
209 mortality data in post-MI HF to HFrEF (though in the absence of confidence intervals) shows  
210 plausible all-cause mortality benefits for these drugs. A possible reason for such strong benefits  
211 could be that most patients in these studies were treated with fibrinolytic therapy or no  
212 reperfusion; data in patients who underwent percutaneous coronary intervention (PCI) post-MI  
213 are limited<sup>19</sup>.

214       Though excluded from the subsequent post-MI analysis shown in Figure 3, the  
215 ALBATROSS trial technically did not study the addition of spironolactone vs. placebo. Instead,  
216 its intervention was the addition of an MRA regimen of potassium canrenoate bolus followed by  
217 6 months of oral spironolactone. As a result, direct comparisons between this trial and RALES<sup>20</sup>  
218 (HFrEF trial) are difficult to make. Furthermore, the confidence intervals reported for all-cause

219 mortality in ALBATROSS were uncharacteristically large in our figure. This could be because  
220 the all-cause death analysis was done in a non-pre-specified exploratory fashion. If done at an  
221 early time point in the study, this could explain the large confidence intervals and could lead to  
222 type I errors.

223 Figure 3 suggests that sacubitril-valsartan is the only drug that reportedly provides an all-  
224 cause mortality benefit in HFrEF, but not post-MI HF. Prior work<sup>21</sup> has noted that sacubitril-  
225 valsartan was studied in a fairly unique [A + B] vs. C design ([sacubitril + valsartan] vs.  
226 enalapril) – a format that continued in its post-MI study PARADISE-MI<sup>22</sup> ([sacubitril +  
227 valsartan] vs. ramipril). Taken together, that the survival trials for sacubitril-valsartan are unique  
228 in both design and outcomes may suggest the need for further trials<sup>32</sup>. Possible trial designs—one  
229 that adopts an [A + B] vs. placebo or [A + B] vs. B design—already exist for sacubitril-valsartan  
230 in HFpEF<sup>24</sup> and in an analysis of NYHA IV HFrEF<sup>25</sup>. Notably, the former study was negative for  
231 both combined heart failure hospitalizations/cardiovascular mortality and all-cause mortality, and  
232 the latter was negative for both primary and secondary endpoints (none of which were all-cause  
233 or cause-specific mortality).

234 Figure 1 suggests that lisinopril shows similarly unique results—demonstrating an all-  
235 cause mortality benefit in post-MI but not HFrEF; however, its registration trial for HFrEF,  
236 ATLAS, reports a combined all-cause morbidity-mortality benefit in HFrEF. This comparison is  
237 further complicated by the fact that ATLAS compared two doses of lisinopril, whereas sacubitril-  
238 valsartan was compared against ramipril. Additionally, as Figure 3 excludes lisinopril’s post-MI  
239 trial (GISSI-3), sacubitril-valsartan appears truly unique among non-acute post-MI HF trials in  
240 demonstrating an asymmetric all-cause mortality benefit. Figure 2 shows that the inclusion  
241 criteria for PARADISE-MI allowed for participants whose MI was between 0.5 and 7 days prior

242 to randomization. This trial therefore did allow for some acutely post-MI participants; however,  
243 the distribution of time-to-randomization was not reported.

244

### 245 **Strengths/Limitations**

246 The major strength of this study is that this is the first comprehensive analysis of all drugs  
247 indicated for heart failure of its kind, and highlights numerous gaps in our understanding of these  
248 drugs' benefits and studied indications. We relied on two data sources (UpToDate and  
249 CenterWatch) to generate a comprehensive list of FDA regulatory approvals for heart failure.

250 There are four limitations to our study. (1) Our search criteria encompass only trials that  
251 measured all-cause mortality as a primary or secondary endpoint. This can be considered a  
252 limitation in situations where other metrics of morbidity or mortality are assessed, but not all-  
253 cause mortality. Additionally, given the diversity of trial designs studied here, a direct head-to-  
254 head comparison between any two drugs can be muddied by the nuances within any given trial—  
255 e.g, the presence or absence of a run-in period, the dose of each drug used, etc.

256 (2) Our search criteria yielded nine drugs in our initial analysis and five drugs in the  
257 subsequent analysis. Given the limited number of drugs available for analysis, the true strength  
258 of the linear relationship established in our regression model may be tenuous or uncertain; future  
259 trials may provide more data points to modulate the relationship.

260 (3) Though our analysis of post-MI trials focused on the times-to-randomization and  
261 LVEF, there were other sub-analyses that could have been done for this set of trials. Many trials  
262 report sub-analyses divided by location of myocardial infarct (e.g anterior, anterolateral) or the  
263 presence/absence of ST-elevations on electrocardiogram. As another example, the SAVE and  
264 AIRE trials—though both post-MI HF trials—differed in whether the patients were in symptomatic

265 HF despite both trials including only patients with an ejection fraction of <40%. These groupings  
266 are certainly additional opportunities for further characterizing post-MI trials that could provide  
267 insight into contexts for which particular drugs are more or less efficacious.

268 (4) This analysis was restricted to only registration survival data and included no long-  
269 term follow-up metrics of morbidity or mortality. Thus, any long-term reports that further guided  
270 or modulated the use of any drugs listed here—for example, a follow-up analysis reporting all-  
271 cause mortality benefit despite the registration trial not reporting such—is not accounted for in  
272 this analysis. Similarly, our extrapolation of incomplete data assumes a linear relationship  
273 between HFrEF and post-MI HF and did not allow us to impute confidence intervals for any HR  
274 predictions.

275

## 276 **Conclusion**

277 Our study provides important insights into the current asymmetries in assessing the  
278 indications for heart failure drugs. We found that only five of 23 drugs indicated for heart failure  
279 have been studied in both HFrEF and post-MI HF. Our imputation of all-cause mortality metrics  
280 for dapagliflozin, empagliflozin, and other drugs may provide insight into future directions for  
281 clinical trials of currently approved heart failure drugs. We predict that the trials DAPA-MI and  
282 EMPACT-MI will report HRs of 0.89 and 0.85, respectively. As these two studies come to  
283 completion in the summer of 2023, our modeling will be further modulated and possibly  
284 substantiated. Older therapies that lack randomized trials may also be tested by non-conflicted  
285 bodies, including the VA or National Institutes of Health.

286

287

288

289 **Contributors:** VP conceptualized study design; CD reviewed the literature; CD curated data; VP  
290 and AH reviewed and confirmed abstracted data; CD wrote the first draft of the manuscript and  
291 all authors reviewed and revised subsequent and finalized draft of the manuscript

292

293 **Sources of Funding & Disclosures:** Vinay Prasad's Disclosures. (Research funding) Arnold

294 Ventures (Royalties) Johns Hopkins Press, Medscape, and MedPage (Honoraria) Grand

295 Rounds/lectures from universities, medical centers, non-profits, and professional societies.

296 (Consulting) UnitedHealthcare and OptumRX. (Other) Plenary Session podcast has Patreon

297 backers, YouTube, and Substack. Alyson Haslam has no disclosures to report. Christopher

298 Dasaro has no disclosures to report.

299

300

301 **References:**

- 302 1. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients  
303 With Chronic Coronary Disease: A Report of the American Heart Association/American  
304 College of Cardiology Joint Committee on Clinical Practice Guidelines | Journal of the  
305 American College of Cardiology. Accessed August 3, 2023.  
306 <https://www.jacc.org/doi/10.1016/j.jacc.2023.04.003#sectitle0045>
- 307 2. AstraZeneca. *A Registry-Based, Randomised, Double-Blind, Placebo-Controlled*  
308 *Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on*  
309 *Cardiometabolic Outcomes in Patients Without Diabetes With Acute Myocardial*  
310 *Infarction at Increased Risk for Subsequent Development of Heart Failure.*  
311 clinicaltrials.gov; 2023. Accessed July 21, 2023.  
312 <https://clinicaltrials.gov/study/NCT04564742>
- 313 3. Boehringer Ingelheim. *EMPACT-MI: A Streamlined, Multicentre, Randomised, Parallel*  
314 *Group, Double-Blind Placebo-Controlled Superiority Trial to Evaluate the Effect of*  
315 *EMPAgliflozin on Hospitalisation for Heart Failure and Mortality in Patients With*  
316 *ACuTe Myocardial Infarction.* clinicaltrials.gov; 2023. Accessed July 21, 2023.  
317 <https://clinicaltrials.gov/study/NCT04509674>
- 318 4. Primary pharmacologic therapy for heart failure with reduced ejection fraction -  
319 UpToDate. Accessed July 23, 2023. [https://www.uptodate.com/contents/primary-  
320 pharmacologic-therapy-for-heart-failure-with-reduced-ejection-  
321 fraction?search=heart%20failure%20reduced%20ejection%20fraction&source=search\\_re  
322 sult&selectedTitle=2~150&usage\\_type=default&display\\_rank=2#H860014988](https://www.uptodate.com/contents/primary-pharmacologic-therapy-for-heart-failure-with-reduced-ejection-fraction?search=heart%20failure%20reduced%20ejection%20fraction&source=search_result&selectedTitle=2~150&usage_type=default&display_rank=2#H860014988)
- 323 5. Heart Failure | FDA Approved Drugs | CenterWatch. Accessed August 3, 2023.  
324 [https://www.centerwatch.com/directories/1067-fda-approved-drugs/topic/388-heart-  
325 failure](https://www.centerwatch.com/directories/1067-fda-approved-drugs/topic/388-heart-failure)
- 326 6. FDALabel. Accessed August 3, 2023. <https://nctr-crs.fda.gov/fdalabel/ui/search>
- 327 7. Jenča D, Melenovský V, Stehlik J, et al. Heart failure after myocardial infarction:  
328 incidence and predictors. *ESC Heart Fail.* 2021;8(1):222-237. doi:[10.1002/ehf2.13144](https://doi.org/10.1002/ehf2.13144)
- 329 8. Kluyver, T. et al., 2016. Jupyter Notebooks – a publishing format for reproducible  
330 computational workflows. In F. Loizides & B. Schmidt, eds. *Positioning and Power in*  
331 *Academic Publishing: Players, Agents and Agendas.* pp. 87–90.
- 332 9. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high  
333 doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and  
334 mortality in chronic heart failure. ATLAS Study Group. *Circulation.* 1999;100(23):2312-  
335 2318. doi:[10.1161/01.cir.100.23.2312](https://doi.org/10.1161/01.cir.100.23.2312)
- 336 10. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-  
337 week mortality and ventricular function after acute myocardial infarction. Gruppo



- 338 Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. *Lancet*.  
339 1994;343(8906):1115-1122.
- 340 11. Cohn JN, Tognoni G. A Randomized Trial of the Angiotensin-Receptor Blocker  
341 Valsartan in Chronic Heart Failure. *New England Journal of Medicine*.  
342 2001;345(23):1667-1675. doi:[10.1056/NEJMoa010713](https://doi.org/10.1056/NEJMoa010713)
- 343 12. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, Captopril, or Both in  
344 Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or  
345 Both. *New England Journal of Medicine*. 2003;349(20):1893-1906.  
346 doi:[10.1056/NEJMoa032292](https://doi.org/10.1056/NEJMoa032292)
- 347 13. Mortality. *American Journal of Cardiology*. 1985;56(14):G15-G22. doi:[10.1016/0002-](https://doi.org/10.1016/0002-9149(85)90691-5)  
348 [9149\(85\)90691-5](https://doi.org/10.1016/0002-9149(85)90691-5)
- 349 14. Swedberg K, Held P, Kjeksus J, Rasmussen K, Rydén L, Wedel H. Effects of the Early  
350 Administration of Enalapril on Mortality in Patients with Acute Myocardial Infarction.  
351 *New England Journal of Medicine*. 1992;327(10):678-684.  
352 doi:[10.1056/NEJM199209033271002](https://doi.org/10.1056/NEJM199209033271002)
- 353 15. Beygui F, Cayla G, Roule V, et al. Early Aldosterone Blockade in Acute Myocardial  
354 Infarction. *Journal of the American College of Cardiology*. 2016;67(16):1917-1927.  
355 doi:[10.1016/j.jacc.2016.02.033](https://doi.org/10.1016/j.jacc.2016.02.033)
- 356 16. Pfeffer MA, Braunwald E, Moyé LA, et al. Effect of Captopril on Mortality and  
357 Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction.  
358 *New England Journal of Medicine*. 1992;327(10):669-677.  
359 doi:[10.1056/NEJM199209033271001](https://doi.org/10.1056/NEJM199209033271001)
- 360 17. Køber L, Torp-Pedersen C, Carlsen JE, et al. A Clinical Trial of the Angiotensin-  
361 Converting-Enzyme Inhibitor Trandolapril in Patients with Left Ventricular Dysfunction  
362 after Myocardial Infarction. *New England Journal of Medicine*. 1995;333(25):1670-  
363 1676. doi:[10.1056/NEJM199512213332503](https://doi.org/10.1056/NEJM199512213332503)
- 364 18. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction  
365 with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE)  
366 Study Investigators. *Lancet*. 1993;342(8875):821-828.
- 367 19. Angiotensin converting enzyme inhibitors and receptor blockers in acute myocardial  
368 infarction: Clinical trials - UpToDate. Accessed July 23, 2023.  
369 [https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-and-](https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-clinical-trials#H2)  
370 [receptor-blockers-in-acute-myocardial-infarction-clinical-trials#H2](https://www.uptodate.com/contents/angiotensin-converting-enzyme-inhibitors-and-receptor-blockers-in-acute-myocardial-infarction-clinical-trials#H2)

- 371 20. Pitt B, Zannad F, Remme WJ, et al. The Effect of Spironolactone on Morbidity and  
372 Mortality in Patients with Severe Heart Failure. *New England Journal of Medicine*.  
373 1999;341(10):709-717. doi:[10.1056/NEJM199909023411001](https://doi.org/10.1056/NEJM199909023411001)
- 374 21. Ahn R, Prasad V. Do Limitations in the Design of PARADIGM-HF Justify the Slow  
375 Real World Uptake of Sacubitril/Valsartan (Entresto)? *Cardiovasc Drugs Ther*.  
376 2018;32(6):633-635. doi:[10.1007/s10557-018-6830-x](https://doi.org/10.1007/s10557-018-6830-x)
- 377 22. Pfeffer MA, Claggett B, Lewis EF, et al. Angiotensin Receptor–Neprilysin Inhibition in  
378 Acute Myocardial Infarction. *N Engl J Med*. 2021;385(20):1845-1855.  
379 doi:[10.1056/NEJMoa2104508](https://doi.org/10.1056/NEJMoa2104508)
- 380 23. Haslam A, Prasad V. Confirmatory Trials for Drugs Approved on a Single Trial.  
381 doi:[10.1161/CIRCOUTCOMES.119.005494](https://doi.org/10.1161/CIRCOUTCOMES.119.005494)
- 382 24. Pieske B, Wachter R, Shah SJ, et al. Effect of Sacubitril/Valsartan vs Standard Medical  
383 Therapies on Plasma NT-proBNP Concentration and Submaximal Exercise Capacity in  
384 Patients With Heart Failure and Preserved Ejection Fraction: The PARALLAX  
385 Randomized Clinical Trial. *JAMA*. 2021;326(19):1919-1929.  
386 doi:[10.1001/jama.2021.18463](https://doi.org/10.1001/jama.2021.18463)
- 387 25. Mann DL, Givertz MM, Vader JM, et al. Effect of Treatment With Sacubitril/Valsartan  
388 in Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized  
389 Clinical Trial. *JAMA Cardiology*. 2022;7(1):17-25. doi:[10.1001/jamacardio.2021.4567](https://doi.org/10.1001/jamacardio.2021.4567)  
390

391 **Tables & Figures:**

392

393 **Table 1:** Drugs included from UpToDate<sup>A</sup> and CenterWatch<sup>B</sup>

Sacubitril-valsartan <sup>AB</sup>	Carvedilol <sup>A</sup>
Enalapril <sup>A</sup>	Bisoprolol <sup>A</sup>
Lisinopril <sup>A</sup>	Spironolactone <sup>A</sup>
Captopril <sup>A</sup>	Eplerenone <sup>A</sup>
Trandolapril <sup>A</sup>	Dapagliflozin <sup>AB</sup>
Ramipril <sup>A</sup>	Empagliflozin <sup>AB</sup>
Losartan <sup>A</sup>	Isosorbide/hydralazine <sup>AB</sup>
Candesartan <sup>A</sup>	Vericiguat <sup>AB</sup>
Valsartan <sup>AB</sup>	Ivabradine <sup>AB</sup>
Metoprolol <sup>AB</sup>	Digoxin <sup>A</sup>

394

395 **Table 2:** Drug and trial characteristics for all HFrEF/post-MI therapies included in analysis


	Number (+pending**)
Number of included drugs from UpToDate and CenterWatch	20
Drugs with all-cause mortality data in either HFrEF or post-MI HF	20
Total number of trials included in analysis	29 (2)
Drugs with all-cause mortality data for HFrEF, only	9 (2)
Drugs with all-cause mortality data for post-MI, only	3
Drugs with all-cause mortality data for both HFrEF and post-MI	9 (2)
Drugs with all-cause mortality data for both HFrEF and non-acute post-MI HF	5 (2)
Drugs with all-cause mortality data for both HFrEF and post-MI HF; active-controls	2
Drugs with all-cause mortality data for both HFrEF and post-MI HF; placebo-controls	4 (2)
Drugs with all-cause mortality data for both HFrEF and post-MI-HF, “mixed” active/placebo-controls	2

396 \*\*Two trials, DAPA-MI and EMPACT-MI, are projected to be completed in June 2023 and  
 397 August 2023, respectively

398


399

400  
401 **Figure 1: All-cause mortality data for drugs indicated for both HFrEF and post-MI.**  
402 Drugs were labeled as being studied against placebo-controls, active-controls, or a combination  
403 (“mixed”). The height and width of the gray ellipses indicate the reported 95% confidence  
404 interval along either axis.




405  
406

407 **Figure 2: Time between onset of MI and randomization, reported in days, in post-MI trials.**




408  
409

410 **Figure 3: All-cause mortality data for drugs indicated for both HF<sub>r</sub>EF and non-acute (>3**  
411 **days) post-MI heart failure.**




412  
413

414 **Figure 4A: Placebo-controlled HF drugs with EMPACT-MI (empagliflozin) and DAPA-MI**  
415 **(dapagliflozin) HR predictions of 0.85 and 0.89, respectively.**  
416




417  
418  
419

420 **Figure 4B: Active-controlled drugs indicated for HFrEF and post-MI HF**  
421





423 **Figure S1A-D: Predicted all-cause mortality metrics for 12 drugs that were missing either**  
424 **HFrEF or post-MI HF data.** The linear regression to which they were fitted is the same as the  
425 placebo-controlled regression. These drugs are broken up by class with all-cause mortality  
426 metrics given as cartesian coordinates (HFrEF, post-MI HF); \* indicates predicted value from  
427 regression: **A**) ACE inhibitors: trandolapril (0.66\*, 0.78); captopril (0.70\*, 0.81); ramipril (0.75\*,  
428 0.84); lisinopril (0.92, 0.88\*). **B**) ARBs: candesartan (0.88, 0.92\*). **C**) MRAs and other classes:  
429 isosorbide/hydralazine (0.61, 0.75\*); spironolactone (0.70, 0.81\*); ivabradine (0.90, 0.93\*);  
430 vericiguat (0.95, 0.96\*); digoxin (0.99, 0.98\*). **D**) Beta blockers: metoprolol (0.66, 0.78\*);  
431 bisoprolol (0.66, 0.78\*).



432  
433  
434

435

436 **Table S1: Characteristics of post-MI trials**

<b>Post-MI Trial</b>	<b>LVEF (%)</b>	<b>Participants Randomized</b>	<b>Intervention vs Control</b>	<b>All-Cause Mortality HR/RR (95% CI)</b>
MIAMI (1985)	N/a	5,778	Metoprolol vs Placebo	0.64 (N/a)
SAVE (1992)	<40%	2,231	Captopril vs Placebo	0.81 (0.68-0.97)
CONSENSUS-II	N/a	6,090	Enalapril vs Placebo	0.92 (N/a)
AIRE (1993)	<40%	2,006	Ramipril vs Placebo	0.84 (0.75-0.95)
GISSI-3 (1994)	N/a	19,394	Lisinopril vs Placebo	0.88 (0.79-0.99)
TRACE (1995)	<35%	1,749	Trandolapril vs Placebo	0.78 (0.67-0.91)
CAPRICORN (2001)	<40%	1,959	Carvedilol vs Placebo	0.77 (0.60-0.98)
OPTIMAAL (2002)	<35%	5,477	Losartan vs Captopril	1.13 (0.99-1.28)
VALIANT (2003)	<35%	9,818	Valsartan vs Captopril	1.00 (0.90-1.10)
EPHESUS (2003)	<40%	6,642	Eplerenone vs Placebo	0.85 (0.75-0.86)
ALBATROSS (2016)	50% **	1,616	MRA regimen vs Std of Care	0.65 (0.30-1.38)
PARADISE-MI (2021)	<40%	5,211	Sacubitril-valsartan vs Ramipril	0.88 (0.73-1.05)
DAPA-MI (2023)	<40%	4,017	Dapagliflozin vs Placebo	TBA
EMPACT-MI (2023)	<45%	6,522	Empagliflozin vs Placebo	TBA

437 \*\*The reported LVEF range was 45-60%; the average in both arms was 50%

438 **Table S2: Characteristics of HFREF trials**

<b>HFREF Trial</b>	<b># Randomized</b>	<b>Intervention vs Control</b>	<b>All-Cause Mortality HR/RR (95% CI)</b>
SOLVD (1991)	2,549	Enalapril vs. placebo	0.84 (0.74-0.95)
DIG (1997)	6,800	Digoxin vs placebo	0.99 (0.91-1.07)
ATLAS (1999)	3,164	High vs low dose lisinopril	0.92 (0.82-1.03)
CIBIS II (1999)	2,647	Bisoprolol vs placebo	0.66 (0.54-0.81)
MERIT-HF (1999)	3,991	Metoprolol vs placebo	0.66 (0.53-0.81)
RALES (1999)	1,663	Spironolactone vs placebo	0.70 (0.69-0.81)
ELITE II (2000)	3,152	Losartan vs captopril	1.13 (0.97-1.35)
COPERNICUS (2001)	2,289	Carvedilol vs placebo	0.65 (0.52-0.81)
Val-HeFT (2001)	2,289	Valsartan vs placebo	1.02 (0.88-1.18)
A-Heft (2004)	1,050	Isosorbide/hydralazine vs placebo	0.61 (N/a)*
CHARM (2004)	4,576	Candesartan vs placebo	0.88 (0.79-0.97)
SHIFT (2010)	6,558	Ivabradine vs placebo	0.90 (0.80-1.02)
EMPHASIS-HF (2011)	2,737	Eplerenone vs placebo	0.76 (0.62-0.93)
PARADIGM-HF	8,399	Sacubitril-valsartan vs enalapril	0.84 (0.76-0.93)
DAPA-HF (2019)	4,744	Dapagliflozin vs placebo	0.83 (0.71-0.97)
EMPEROR-Reduced (2020)	3,730	Empagliflozin vs placebo	0.76 (0.62-0.93)
VICTORIA (2020)	2,526	Vericiguat vs placebo	0.95 (0.85-1.07)

439

440